Market Research Reports and Industry Reports

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION

Over the years, the nuclear medicine/radiopharmaceuticals market has witnessed various advancements in radiopharmaceuticals. The global nuclear medicine/radiopharmaceuticals market is growing due to the increasing number of radioisotope approvals for different clinical indications. Tc-99m and F-18 are estimated to be the highest contributors to the nuclear medicine/radiopharmaceuticals diagnostics market; whereas, Ra-223, I-131, and Y-90 are estimated to be the highest contributors for the nuclear medicine/radiopharmaceuticals therapeutics market in 2015.
 
 In 2015, the diagnostics segment accounted for the largest share of the nuclear medicine/radiopharmaceuticals market, by type; the SPECT segment accounted for the largest share of the nuclear medicine/radiopharmaceuticals diagnostics market; whereas, the beta emitters segment accounted for the largest share of the nuclear medicine/radiopharmaceuticals therapeutics market.
 
 In 2015, North America accounted for the largest share of the nuclear medicine/radiopharmaceuticals market, followed by Asia-Pacific, Europe, and the Rest of the World (RoW). In the coming years, the Asia-Pacific region is expected to witness the highest growth rate for the nuclear medicine/radiopharmaceuticals market, with an emphasis on India, China, Japan, and Australia. These countries are expected to be lucrative markets for the manufacturers of radiopharmaceuticals.
 
 The global nuclear medicine/radiopharmaceuticals market witnesses high-competitive intensity as there are several large and small firms with similar product offerings. These companies adopt various strategies (agreements, contracts, partnerships, expansions, acquisitions, market development, new product launches, marketing and promotional activities, technological enhancements, and website launches) to increase their market shares and to establish a strong foothold in the global market.
 
 Reasons to Buy the Report:
 
 The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
 
 The report provides insights on the following pointers:
 
 • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the nuclear medicine/radiopharmaceuticals market. The report analyzes the nuclear medicine/radiopharmaceuticals market by type, and application, and procedural volume
 
 • Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the nuclear medicine/radiopharmaceuticals market
 
 • Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various nuclear medicine/radiopharmaceuticals technologies across regions
 
 • Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the nuclear medicine/radiopharmaceuticals market
 
 • Competitive Assessment: In-depth assessment of the market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the nuclear medicine/radiopharmaceuticals market

 1 INTRODUCTION 19
 1.1 OBJECTIVES OF STUDY 19
 1.2 MARKET DEFINITION 19
 1.3 MARKET SCOPE 19
 1.3.1 MARKETS COVERED 20
 1.3.2 YEARS CONSIDERED FOR THE STUDY 21
 1.4 CURRENCY 21
 1.5 LIMITATIONS 21
 1.6 STAKEHOLDERS 21
 2 RESEARCH METHODOLOGY 22
 2.1 RESEARCH METHODOLOGY STEPS 22
 2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 23
 2.2.1 SECONDARY RESEARCH 23
 2.2.2 PRIMARY RESEARCH 24
 2.2.3 KEY INDUSTRY INSIGHTS 24
 2.3 KEY DATA FROM PRIMARY SOURCES 25
 2.4 KEY INSIGHTS FROM PRIMARY SOURCES 26
 2.5 MARKET SIZE ESTIMATION METHODOLOGY 26
 2.6 RESEARCH DESIGN 28
 2.7 MARKET DATA VALIDATION AND TRIANGULATION 29
 2.8 ASSUMPTIONS FOR THE STUDY 29
 3 EXECUTIVE SUMMARY 30
 3.1 INTRODUCTION 30
 3.2 CURRENT SCENARIO 31
 3.3 FUTURE OUTLOOK 31
 3.4 CONCLUSION 33
 4 PREMIUM INSIGHTS 34
 4.1 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 34
 4.2 SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTICS MARKET, BY REGION AND APPLICATION 35
 4.3 REGIONAL SNAPSHOT OF THE NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 36
 4.4 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE (2015 VS. 2020) 37
 5 MARKET OVERVIEW 38
 5.1 INTRODUCTION 39
 5.2 MARKET DYNAMICS 39
 5.2.1 DRIVERS 40
 5.2.1.1 Increasing preference for SPECT and PET scans 40
 5.2.1.2 Advances in radiotracers 40
 5.2.1.3 Alpha radio immunotherapy-based targeted cancer treatment 40
 5.2.1.4 Increasing incidence of cancer and cardiac ailments 41
 5.2.2 RESTRAINTS 42
 5.2.2.1 Shorter half-life of radiopharmaceuticals restricts its usage 42
 5.2.2.2 Stringent regulatory and GMP guidelines 42
 5.2.2.3 Competition from conventional diagnostic procedures 43
 5.2.3 OPPORTUNITIES 44
 5.2.3.1 Potential radioisotopes in the pipeline 44
 5.2.3.2 High demand in emerging markets 44
 5.2.3.3 Neurological applications 44
 5.2.4 THREAT 45
 5.2.4.1 Shutdown of nuclear reactors 45
 6 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE 47
 6.1 INTRODUCTION 48
 6.2 DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 50
 6.2.1 SPECT RADIOPHARMACEUTICALS 52
 6.2.1.1 Technetium-99m (Tc-99m) 53
 6.2.1.2 Thallium-201 (Tl-201) 54
 6.2.1.3 Gallium-67 (Ga-67) 55
 6.2.1.4 Iodine (I-123) 56
 6.2.1.5 Others 56
 6.2.2 PET RADIOPHARMACEUTICALS 57
 6.2.2.1 Fluorine-18 (F-18) 59
 6.2.2.2 Rubidium-82 (Rb-82) 60
 6.2.2.3 Others 60
 6.3 THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 61
 6.3.1 BETA EMITTERS 63
 6.3.1.1 Iodine-131 (I-131) 65
 6.3.1.2 Yttrium-90 (Y-90) 66
 6.3.1.3 Samarium-153 (Sm-153) 66
 6.3.1.4 Rhenium-186 (Re-186) 67
 6.3.1.5 Lutetium-177 (Lu-177) 68
 6.3.1.6 Others 68
 6.3.2 ALPHA EMITTERS 69
 6.3.2.1 Radium-223 (Ra-223) 70
 6.3.3 BRACHYTHERAPY 71
 6.3.3.1 Iodine-125 72
 6.3.3.2 Iridium-192 73
 6.3.3.3 Palladium-103 74
 6.3.3.4 Cesium-131 74
 6.3.3.5 Others 75
 7 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUME 76
 7.1 INTRODUCTION 77
 7.2 DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 78
 7.2.1 SPECT RADIOPHARMACEUTICALS 79
 7.2.2 PET RADIOPHARMACEUTICALS 80
 7.3 THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 81
 7.3.1 BETA EMITTERS 82
 7.3.2 ALPHA EMITTERS 83
 7.3.3 BRACHYTHERAPY 84
 8 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION 85
 8.1 INTRODUCTION 86
 8.2 DIAGNOSTIC APPLICATIONS 86
 8.2.1 SPECT APPLICATIONS 86
 8.2.1.1 Cardiology 89
 8.2.1.2 Lymphoma 89
 8.2.1.3 Neurology 91
 8.2.1.4 Thyroid 92
 8.2.1.5 Other Diagnostic Applications 93
 8.2.2 PET APPLICATIONS 93
 8.2.2.1 Oncology 96
 8.2.2.2 Cardiology 96
 8.2.2.3 Neurology 97
 8.2.2.4 Other PET Applications 98
 8.3 THERAPEUTIC APPLICATIONS 99
 8.3.1 THYROID 101
 8.3.2 BONE METASTASIS 102
 8.3.3 LYMPHOMA 103
 8.3.4 ENDOCRINE TUMORS 104
 8.3.5 OTHER THERAPEUTIC APPLICATIONS 104
 9 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY REGION 106
 9.1 INTRODUCTION 107
 9.2 DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 108
 9.2.1 NORTH AMERICA 109
 9.2.1.1 DEVELOPMENT OF MO-99 PRODUCTION FACILITIES IN THE U.S. 110
 9.2.1.2 FDA APPROVALS OF NEW RADIOPHARMACEUTICALS 110
 9.2.1.3 EXTENSION OF OPERATIONS IN THE CANADIAN NATIONAL RESEARCH UNIVERSAL (NRU) REACTOR 110
 9.2.1.4 DEVELOPMENT OF ALTERNATIVE MEDICAL ISOTOPE TECHNOLOGIES IN CANADA 110
 9.2.2 EUROPE 113
 9.2.2.1 INCREASING ACCEPTABILITY OF 18F-FDG PET-CT IN THE U.K. 114
 9.2.2.2 SHUTDOWN OF FRENCH NUCLEAR REACTOR 114
 9.2.2.3 NEW IRRADIATION FACILITY IN GERMANY 115
 9.2.3 ASIA-PACIFIC 118
 9.2.3.1 INTRODUCTION OF NEW COST-EFFECTIVE TC-99 GENERATORS IN INDIA 119
 9.2.3.2 HIGH INCIDENCE OF CANCER AND CARDIOVASCULAR DISEASE IN CHINA 119
 9.2.3.3 INCREASING MO-99 PRODUCTION IN AUSTRALIA 119
 9.2.3.4 INITIATIVES TO PROMOTE HEALTH IN ASIA-PACIFIC 119
 9.2.4 REST OF THE WORLD 123
 9.2.4.1 DEVELOPMENT OF MULTIPURPOSE RESEARCH REACTOR IN BRAZIL 124
 9.2.4.2 ARGENTINA’S INCREASING IRRADIATION CAPACITY 124
 9.2.4.3 CONVERSION OF THE SAFARI 1 REACTOR, FROM HEU-BASED MO-99 PRODUCTION TO LEU 124
 9.3 THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 127
 9.3.1 NORTH AMERICA 127
 9.3.1.1 FDA approval for alpha emitters in the U.S. 128
 9.3.1.2 Therapeutic nuclear medicine, an alternative choice of treatment in oncology 129
 9.3.1.3 Increase in the incidence of thyroid cancer 129
 9.3.1.4 Expertise in isotope production 129
 9.3.1.5 Government initiatives 129
 9.3.1.6 High incidence of cancer 130
 9.3.2 EUROPE 132
 9.3.2.1 Increasing awareness of radioisotope therapy in the U.K. 133
 9.3.2.2 Adverse reactions to radiopharmaceuticals in France 133
 9.3.2.3 Radionuklidtherapeutika—research program conducted in Germany 134
 9.3.2.4 Russia, an upcoming country for radionuclide therapy 134
 9.3.3 ASIA-PACIFIC 136
 9.3.3.1 Increased production of radiopharmaceuticals for therapeutic purposes in India 138
 9.3.3.2 Aging population and increasing cancer incidence 138
 9.3.3.3 Approval of radium (223Ra) dichloride by the therapeutic goods administration (TGA) 138
 9.3.4 REST OF THE WORLD(ROW) 141
 9.3.4.1 Growing aging population 141
 9.3.4.2 Increase in cancer incidences 141
 10 COMPETITIVE LANDSCAPE 144
 10.1 OVERVIEW 144
 10.2 MARKET SHARE ANALYSIS 144
 10.2.1 INTRODUCTION 144
 10.2.2 CARDINAL HEALTH, INC. 145
 10.2.3 MALLINCKRODT PLC 146
 10.2.4 GE HEALTHCARE 147
 10.2.5 LANTHEUS MEDICAL IMAGING, INC. 148
 10.2.6 BAYER HEALTHCARE 149
 10.3 COMPETITIVE SITUATION AND TRENDS 151
 10.3.1 INTRODUCTION 151
 10.3.2 AGREEMENTS, CONTRACTS, AND PARTNERSHIPS 152
 10.3.3 ACQUISITIONS 153
 10.3.4 MARKET DEVELOPMENT 154
 10.3.5 EXPANSION 154
 10.3.6 NEW PRODUCT LAUNCHES 155
 10.3.7 OTHERS 156
 11 COMPANY PROFILES 157
 11.1 INTRODUCTION 157
 11.2 CARDINAL HEALTH, INC. 158
 11.2.1 BUSINESS OVERVIEW 158
 11.2.2 PRODUCTS AND SERVICES 159
 11.2.3 RECENT DEVELOPMENTS 159
 11.2.4 MNM VIEW 160
 11.3 MALLINCKRODT PLC 161
 11.3.1 BUSINESS OVERVIEW 161
 11.3.2 PRODUCT OFFERINGS 162
 11.3.3 RECENT DEVELOPMENTS 162
 11.3.4 MNM VIEW 162
 11.4 GE HEALTHCARE 163
 11.4.1 BUSINESS OVERVIEW 163
 11.4.2 PRODUCT PORTFOLIO 164
 11.4.3 RECENT DEVELOPMENTS 164
 11.4.4 MNM VIEW 165
 11.5 LANTHEUS MEDICAL IMAGING, INC. 166
 11.5.1 BUSINESS OVERVIEW 166
 11.5.2 PRODUCT OFFERINGS 167
 11.5.3 RECENT DEVELOPMENTS 167
 11.5.4 MNM VIEW 167
 11.6 BAYER HEALTHCARE 168
 11.6.1 BUSINESS OVERVIEW 168
 11.6.2 PRODUCT OFFERINGS 169
 11.6.3 RECENT DEVELOPMENTS 169
 11.6.4 MNM VIEW 169
 11.7 BRACCO IMAGING S.P.A 170
 11.7.1 BUSINESS OVERVIEW 170
 11.7.2 PRODUCT OFFERINGS 171
 11.7.3 RECENT DEVELOPMENTS 171
 11.8 ECZACIBASI-MONROL NUCLEAR PRODUCTS 172
 11.8.1 BUSINESS OVERVIEW 172
 11.8.2 PRODUCTS AND SERVICES 172
 11.8.3 RECENT DEVELOPMENTS 173
 11.9 NORDION, INC. 174
 11.9.1 BUSINESS OVERVIEW 174
 11.9.2 PRODUCT OFFERINGS 175
 11.9.3 RECENT DEVELOPMENTS 175
 11.10 ADVANCED ACCELERATOR APPLICATIONS S.A. 176
 11.10.1 BUSINESS OVERVIEW 176
 11.10.2 PRODUCT OFFERINGS 177
 11.10.3 RECENT DEVELOPMENTS 177
 11.11 IBA MOLECULAR IMAGING 178
 11.11.1 BUSINESS OVERVIEW 178
 11.11.2 PRODUCT OFFERINGS 178
 11.11.1 RECENT DEVELOPMENTS 179
 12 APPENDIX 180
 12.1 DISCUSSION GUIDE 180
 12.2 COMPANY DEVELOPMENTS (2012–2015) 188
 12.2.1 CARDINAL HEALTH, INC. 188
 12.2.2 BAYER HEALTHCARE 188
 12.3 AVAILABLE CUSTOMIZATIONS 189
 12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 189
 12.5 RELATED REPORTS 190


List Of Tables

 TABLE 1 ALPHA RADIO IMMUNOTHERAPY-BASED TARGETED CANCER TREATMENT TO BOOST THE GROWTH OF THE NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 41
 TABLE 2 SHORTER HALF-LIFE OF RADIOPHARMACEUTICALS RESTRAINING THE GROWTH OF THE NUCLEAR MEDICINE MARKET 43
 TABLE 3 POTENTIAL RADIOISOTOPES IN THE PIPELINE OFFER SIGNIFICANT GROWTH OPPORTUNITIES FOR THE NUCLEAR MEDICINE MARKET 45
 TABLE 4 SHUTDOWN OF NUCLEAR REACTORS IS A MAJOR CHALLENGE IN THIS MARKET 46
 TABLE 5 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 49
 TABLE 6 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR DIAGNOSTIC SEGMENT, BY REGION, 2013-2020 ($MILLION) 50
 TABLE 7 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR DIAGNOSTIC ISOTOPES, BY TYPE, 2013-2020 ($MILLION) 51
 TABLE 8 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT ISOTOPES, BY REGION, 2013-2020 ($MILLION) 52
 TABLE 9 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY ISOTOPE TYPE, 2013-2020 ($MILLION) 53
 TABLE 10 GLOBAL SPECT MARKET SIZE FOR TECHNETIUM-99M ISOTOPES, BY REGION, 2013-2020 ($MILLION) 54
 TABLE 11 GLOBAL SPECT MARKET SIZE FOR THALLIUM-201 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 54
 TABLE 12 GLOBAL SPECT MARKET SIZE FOR GALLIUM-67 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 55
 TABLE 13 GLOBAL SPECT MARKET SIZE FOR IODINE-123 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 56
 TABLE 14 GLOBAL SPECT MARKET SIZE FOR OTHER ISOTOPES, BY REGION, 2013-2020 ($MILLION) 57
 TABLE 15 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET ISOTOPES, BY REGION, 2013-2020 ($MILLION) 58
 TABLE 16 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY ISOTOPE, 2013-2020 ($MILLION) 58
 TABLE 17 GLOBAL PET MARKET SIZE FOR FLUORINE-18 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 59
 TABLE 18 GLOBAL PET MARKET SIZE FOR RUBIDIUM-82 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 60
 TABLE 19 GLOBAL PET ISOTOPES MARKET SIZE FOR OTHER ISOTOPES, BY REGION, 2013-2020 ($MILLION) 61
 TABLE 20 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC ISOTOPES, BY REGION, 2013-2020 ($MILLION) 62
 TABLE 21 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC ISOTOPES, BY TYPE, 2013-2020 ($MILLION) 62
 TABLE 22 GLOBAL BETA EMITTERS MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 64
 TABLE 23 GLOBAL BETA EMITTERS MARKET SIZE, BY ISOTOPE, 2013-2020 ($MILLION) 64
 TABLE 24 GLOBAL BETA EMITTERS MARKET SIZE FOR IODINE-131 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 65
 TABLE 25 GLOBAL BETA EMITTERS MARKET SIZE FOR YTTRIUM-90 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 66
 TABLE 26 GLOBAL BETA EMITTERS MARKET SIZE FOR SAMARIUM-153 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 67
 TABLE 27 GLOBAL BETA EMITTERS MARKET SIZE FOR RHENIUM-186 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 67
 TABLE 28 GLOBAL BETA EMITTERS MARKET SIZE FOR LUTETIUM-177 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 68
 TABLE 29 GLOBAL BETA EMITTERS MARKET SIZE FOR OTHER ISOTOPES, BY REGION, 2013-2020 ($MILLION) 69
 TABLE 30 GLOBAL ALPHA EMITTERS MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 70
 TABLE 31 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY REGION, 2013-2020 ($MILLION) 72
 TABLE 32 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY ISOTOPES, 2013-2020 ($MILLION) 72
 TABLE 33 GLOBAL BRACHYTHERAPY MARKET SIZE FOR IODINE-125 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 73
 TABLE 34 GLOBAL BRACHYTHERAPY MARKET SIZE FOR IRIDIUM-192 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 73
 TABLE 35 GLOBAL BRACHYTHERAPY MARKET SIZE FOR PALLADIUM-103 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 74
 TABLE 36 GLOBAL BRACHYTHERAPY MARKET SIZE FOR CESIUM-131 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 75
 TABLE 37 GLOBAL BRACHYTHERAPY MARKET SIZE FOR OTHER ISOTOPES, BY REGION, 2013-2020 ($MILLION) 75
 TABLE 38 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 77
 TABLE 39 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC PROCEDURES MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND) 78
 TABLE 40 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 78
 TABLE 41 NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND) 79
 TABLE 42 NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 79
 TABLE 43 NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND) 80
 TABLE 44 NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 80
 TABLE 45 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC PROCEDURES MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND) 81
 TABLE 46 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 81
 TABLE 47 NUCLEAR MEDICINE BETA EMITTERS PROCEDURE MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND) 82
 TABLE 48 NUCLEAR MEDICINE BETA EMITTERS PROCEDURE MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 82
 TABLE 49 NUCLEAR MEDICINE ALPHA EMITTERS PROCEDURE MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND) 83
 TABLE 50 NUCLEAR MEDICINE ALPHA EMITTERS PROCEDURE MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 83
 TABLE 51 NUCLEAR MEDICINE BRACHYTHERAPY PROCEDURES MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND) 84
 TABLE 52 NUCLEAR MEDICINE BRACHYTHERAPY PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 84
 TABLE 53 SEGMENTATION OF NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR SPECT APPLICATIONS, BY TYPE 87
 TABLE 54 NUCLEAR MEDICINE/RADIOPHAMACEUTICALS MARKET SIZE FOR SPECT APPLICATIONS, BY TYPE, 2013-2020 ($MILLION) 88
 TABLE 55 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 89
 TABLE 56 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 90
 TABLE 57 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 91
 TABLE 58 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 92
 TABLE 59 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 93
 TABLE 60 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SEGMENTATION OF PET, BY APPLICATION 94
 TABLE 61 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS, BY TYPE, 2013-2020 ($MILLION) 95
 TABLE 62 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ONCOLOGY PET APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 96
 TABLE 63 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY PET APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 97
 TABLE 64 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY PET APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 98
 TABLE 65 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER PET APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 98
 TABLE 66 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2013–2020($MILLION) 100
 TABLE 67 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 102
 TABLE 68 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BONE METASTASIS THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 103
 TABLE 69 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 103
 TABLE 70 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ENDOCRINE TUMOR THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 104
 TABLE 71 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 105
 TABLE 72 GLOBAL NUCLEAR MEDICINE /RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 107
 TABLE 73 NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 111
 TABLE 74 NORTH AMERICA: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 111
 TABLE 75 NORTH AMERICA: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 112
 TABLE 76 NORTH AMERICA: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 112
 TABLE 77 NORTH AMERICA: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 113
 TABLE 78 EUROPE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 115
 TABLE 79 EUROPE: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 115
 TABLE 80 EUROPE: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 116
 TABLE 81 EUROPE: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 116
 TABLE 82 EUROPE: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 117
 TABLE 83 ASIA-PACIFIC: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 120
 TABLE 84 ASIA-PACIFIC: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 120
 TABLE 85 ASIA-PACIFIC: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 121
 TABLE 86 ASIA-PACIFIC: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 121
 TABLE 87 ASIA-PACIFIC: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 122
 TABLE 88 ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 124
 TABLE 89 ROW: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 125
 TABLE 90 ROW: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 125
 TABLE 91 ROW: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 126
 TABLE 92 ROW: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 126
 TABLE 93 NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 130
 TABLE 94 NORTH AMERICA: NUCLEAR MEDICINE BETA EMITTERS MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 131
 TABLE 95 NORTH AMERICA: NUCLEAR MEDICINE BRACHYTHERAPY MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 131
 TABLE 96 NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 132
 TABLE 97 EUROPE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 134
 TABLE 98 EUROPE: NUCLEAR MEDICINE BETA EMITTERS MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 135
 TABLE 99 EUROPE: NUCLEAR MEDICINE BRACHYTHERAPY MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 135
 TABLE 100 EUROPE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 ($MILLION) 136
 TABLE 101 ASIA-PACIFIC: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 139
 TABLE 102 ASIA-PACIFIC: NUCLEAR MEDICINE BETA EMITTERS MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 139
 TABLE 103 ASIA-PACIFIC: NUCLEAR MEDICINE BRACHYTHERAPY MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 140
 TABLE 104 ASIA-PACIFIC: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 ($MILLION) 140
 TABLE 105 ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 141
 TABLE 106 ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL BETA EMITTERS MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 142
 TABLE 107 ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL BRACHYTHERAPY MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 142
 TABLE 108 ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 143


List Of Figures

FIGURE 1 NUCLEAR MEDICINE/RADIOPHARMACEUTICAL MARKET SEGMENTATION 20
 FIGURE 2 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: RESEARCH METHODOLOGY STEPS 22
 FIGURE 3 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 25
 FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 27
 FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 27
 FIGURE 6 DATA TRIANGULATION METHODOLOGY 29
 FIGURE 7 DIAGNOSTICS MARKET TO WITNESS HIGHEST GROWTH RATE FROM 2015 TO 2020 30
 FIGURE 8 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTICS MARKET SHARE, BY TYPE, 2015–2020 31
 FIGURE 9 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 32
 FIGURE 10 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS SPECT APPLICATIONS, 2015–2020 33
 FIGURE 11 ADVANCES IN RADIOTRACERS TO PROPEL MARKET GROWTH 34
 FIGURE 12 NORTH AMERICA DOMINATES THE SPECT NUCLEAR MEDICINE DIAGNOSTICS MARKET IN 2015 35
 FIGURE 13 ASIA-PACIFIC TO WITNESS HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 36
 FIGURE 14 DIAGNOSTICS SEGMENT TO COMMAND THE LARGEST MARKET SHARE DURING THE FORECAST PERIOD 37
 FIGURE 15 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, CHALLENGES, & OPPORTUNITIES 39
 FIGURE 16 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE 48
 FIGURE 17 THERAPEUTIC SEGMENT TO GROW AT THE HIGHEST CAGR OF 10.5% 49
 FIGURE 18 PET SEGMENT TO GROW AT THE HIGHEST CAGR OF 11.7% DURING THE FORECAST PERIOD 51
 FIGURE 19 ALPHA EMITTERS SEGMENT TO GROW AT THE HIGHEST CAGR OF 17.3% DURING THE FORECAST PERIOD 63
 FIGURE 20 ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR OF 9.4% DURING THE FORECAST PERIOD 87
 FIGURE 21 THE NEUROLOGY APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 8.4% DURING THE FORECAST PERIOD 88
 FIGURE 22 ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR OF 13.1% DURING THE FORECAST PERIOD 94
 FIGURE 23 THE NEUROLOGY APPLICATION SEGMENT IS PROJECTED TO GROW AT THE HIGHEST CAGR OF 12.9% DURING THE FORECAST PERIOD 95
 FIGURE 24 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC APPLICATIONS MARKET SEGMENTATION, BY TYPE 99
 FIGURE 25 ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR OF 12.2% DURING THE FORECAST PERIOD 100
 FIGURE 26 THE ENDOCRINE TUMORS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR OF 11.3% DURING THE FORECAST PERIOD 101
 FIGURE 27 NORTH AMERICA COMMANDS LARGEST SHARE OF THE GLOBAL NUCLEAR MEDICINE DIAGNOSTIC MARKET IN 2015 108
 FIGURE 28 NORTH AMERICA IS LIKELY TO WITNESS A CAGR OF 8.1% DURING THE FORECAST PERIOD 109
 FIGURE 29 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET TO GROW AT A CAGR OF 7.7% DURING THE FORECAST PERIOD 114
 FIGURE 30 ASIA-PACIFIC IS LIKELY TO WITNESS A CAGR OF 10.1% DURING THE FORECAST PERIOD 118
 FIGURE 31 ROW NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET IS LIKELY TO GROW AT A CAGR OF 9% IN THE FORCAST PERIOD 123
 FIGURE 32 NORTH AMERICA IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE GLOBAL NUCLEAR MEDICINE THERAPEUTIC MARKET IN 2015 127
 FIGURE 33 NORTH AMERICA TO WITNESS A CAGR OF 10% IN THE GLOBAL NUCLEAR MEDICINE THERAPEUTIC MARKET DURING THE FORECAST PERIOD 128
 FIGURE 34 EUROPE IS LIKELY TO WITNESS A CAGR OF 9.8% DURING THE FORECAST PERIOD 133
 FIGURE 35 ASIA-PACIFIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET TO GROW AT A CAGR OF 12.2% DURING THE FORECAST PERIOD 137
 FIGURE 36 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014 144
 FIGURE 37 STRATEGIES ADOPTED BY KEY PLAYERS OVER THE LAST THREE YEARS(2012-2015) 151
 FIGURE 38 BATTLE FOR MARKET SHARE: AGREEMENTS/CONTRACTS/PARTNERSHIPS WAS THE KEY STRATEGY (2012 -2015) 152
 FIGURE 39 AGREEMENTS, CONTRACTS, AND PARTNERSHIPS, 2012-2015 153
 FIGURE 40 ACQUISITIONS, 2012-2015 153
 FIGURE 41 MARKET DEVELOPMENT, 2012-2015 154
 FIGURE 42 EXPANSIONS, 2012-2015 155
 FIGURE 43 NEW PRODUCT LAUNCHES, 2012-2015 155
 FIGURE 44 OTHER STRATEGIES, 2012-2015 156
 FIGURE 45 GEOGRAPHICAL REVENUE MIX OF KEY PLAYERS IN THE MARKET 157
 FIGURE 46 CARDINAL HEALTH, INC.: COMPANY SNAPSHOT 158
 FIGURE 47 MALLINCKRODT PLC: COMPANY SNAPSHOT 161
 FIGURE 48 GE HEALTHCARE: COMPANY SNAPSHOT 163
 FIGURE 49 LANTHEUS MEDICAL IMAGING: COMPANY SNAPSHOT 166
 FIGURE 50 BAYER HEALTHCARE: COMPANY SNAPSHOT 168
 FIGURE 51 NORDION, INC.: COMPANY SNAPSHOT 174
 FIGURE 52 ADVANCED ACCELERATOR APPLICATIONS S.A.: COMPANY SNAPSHOT 176


Europe Spent Nuclear Fuel Dry Storage Cask Market Report 2016

Notes:Sales, means the sales volume of Spent Nuclear Fuel Dry Storage CaskRevenue, means the sales value of Spent Nuclear Fuel Dry Storage CaskThis report studies sales (consumption) of Spent Nuclear

USD 3900View Report

UniStar Nuclear Energy, LLC Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

UniStar Nuclear Energy, LLC Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions, SWOT

USD 200View Report

State Nuclear Technology Corporation Ltd Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

State Nuclear Technology Corporation Ltd Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions,

USD 200View Report

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a CAGR of 9.3% in the next five years

USD 5650View Report

United States Nuclear Medicine/Radiopharmaceuticals Industry 2016 Market Research Report

The United States Nuclear Medicine/Radiopharmaceuticals Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Nuclear Medicine/Radiopharmaceuticals industry.The report provides a basic overview

USD 3800View Report

Global Nuclear Medicine/Radiopharmaceuticals Consumption 2016 Market Research Report

The Global Nuclear Medicine/Radiopharmaceuticals Consumption 2016 Market Research Report is a professional and in-depth study on the current state of the Nuclear Medicine/Radiopharmaceuticals market.First, the report provides a basic overview

USD 4000View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 4650
  • Multi User Licence    $ 5650
  • Corporate Licence    $ 7150
  • Enterprise Wide Licence    $ 9000
$ 4650

Reports Details

Published Date : Jul 2015
No. of Pages :191
Country :Global
Category :Healthcare
Publisher :MarketsandMarkets
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment